Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9279369 | Journal of Virological Methods | 2005 | 6 Pages |
Abstract
A capture enzyme-enhanced chemiluminescence immunoassay (ECLIA) based on three specific monoclonal antibodies to detect the nucleocapsid (N) protein of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in the serial serum samples from SARS patients was developed. The anti-SARS-CoV IgG and the viral RNA were also detected in the sera by ELISA and RT-PCR, respectively. During the first 10 days after onset, anti-SARS-CoV IgG, SARS-CoV RNA and the N protein were detected in 21.4, 42.9, and 90% of the patients' sera, respectively. The detection rate of the N protein during days 11-15 of the disease was still significantly higher than those of anti-SARS-CoV IgG and SARS-CoV RNA. The data demonstrated that detection of the N protein with the capture ECLIA appears to be more useful than detection of other viral makers for rapid diagnosis of SARS in patients.
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Yong-Hua Li, Jie Li, Xue-En Liu, Ling Wang, Tong Li, Yi-Hua Zhou, Hui Zhuang,